Logotype for Cadrenal Therapeutics Inc

Cadrenal Therapeutics (CVKD) investor relations material

Cadrenal Therapeutics Lytham Partners Fall 2025 Investor Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Cadrenal Therapeutics Inc
Lytham Partners Fall 2025 Investor Conference summary30 Sep, 2025

Company overview and market focus

  • Focuses on developing novel anticoagulant drugs targeting high-risk and orphan indications within the $38B global oral anticoagulation market, specifically a $2B U.S. segment.

  • Avoids markets dominated by direct oral anticoagulants, instead addressing end-stage kidney disease, left ventricular assist devices, and mechanical heart valves.

  • Lead products are tecarfarin, a next-generation vitamin K antagonist, and frunexian, an IV Factor XIa inhibitor for acute care.

Tecarfarin program updates

  • Tecarfarin is not metabolized by the hepatic cytochrome P450 system, offering more predictable drug levels and fewer drug-drug interactions.

  • Holds orphan drug and fast track designations for ESKD, AFib, and LVADs, with seven years of exclusivity post-approval.

  • Phase II/III ready, with drug product manufactured and a phase II study in dialysis patients planned for early 2026.

  • EmbraceAC study showed tecarfarin matched or outperformed intensively managed warfarin, especially in patients with abnormal metabolism or drug interactions.

  • Demonstrated stable drug levels in severe kidney disease, unlike warfarin, supporting its use in high-risk populations.

Frunexian acquisition and acute care focus

  • Frunexian is a fast-on, fast-off IV Factor XIa inhibitor, uniquely positioned for acute care applications such as complex cardiac surgery.

  • Only Factor XIa inhibitor in development for acute care, with two completed phase I studies.

  • 2026 goals include formulation optimization and advancing towards clinical trials for complex cardiac surgery.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Cadrenal Therapeutics earnings date

Logotype for Cadrenal Therapeutics Inc
Q3 20256 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Cadrenal Therapeutics earnings date

Logotype for Cadrenal Therapeutics Inc
Q3 20256 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Cadrenal Therapeutics, Inc. is a biopharmaceutical company focused on the development of tecarfarin, an advanced oral anticoagulant. Tecarfarin is designed to prevent heart attacks, strokes, and deaths caused by blood clots, particularly in patients with rare cardiovascular conditions that require long-term anticoagulation therapy. These conditions include end-stage kidney disease (ESKD), atrial fibrillation, and complications related to left ventricular assist devices (LVADs). The company aims to address the limitations of existing anticoagulants like warfarin, offering a more stable and reliable treatment option through an alternative metabolic pathway. The company is headquartered in Ponte Vedra, Florida, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage